Assessment of pharmacogenetic tests: Presenting measures of clinical validity and potential population impact in association studies

Pharmacogenomics Journal

Volumn 17, Issue 4, 2017, Pages 386-392

  Tonk, E C M ^a   Gurwitz, D ^b   Maitland Van Der Zee, A H ^c   Janssens, A C J W ^a,d  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b TEL AVIV UNIVERSITY   (Israel)

^c UTRECHT UNIVERSITY   (Netherlands)

^d EMORY UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; CARBAMAZEPINE; FLUOROURACIL; HLA B ANTIGEN; SIMVASTATIN; SOLUTE CARRIER ORGANIC ANION TRANSPORTER 1B1; WARFARIN; 2',3' DIDEOXYNUCLEOSIDE DERIVATIVE;

ARTICLE; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DISCRIMINANT VALIDITY; DISEASE SEVERITY; DRUG COST; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG TOLERABILITY; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HLA B GENE; HUMAN; MEDICATION COMPLIANCE; MYALGIA; MYOPATHY; PHARMACOGENETIC TESTING; PREDICTIVE VALUE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK BENEFIT ANALYSIS; SENSITIVITY AND SPECIFICITY; SLCO1B1 GENE; TREATMENT WITHDRAWAL; ADVERSE DRUG REACTION; GENETIC SCREENING; GENETIC VARIATION; GENETICS; PHARMACOGENETICS; PROCEDURES;

DIDEOXYNUCLEOSIDES; DRUG HYPERSENSITIVITY; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; GENETIC TESTING; GENETIC VARIATION; HLA-B ANTIGENS; HUMANS; PHARMACOGENETICS; SIMVASTATIN;

EID: 84966658548     PISSN: 1470269X     EISSN: 14731150     Source Type: Journal    
DOI: 10.1038/tpj.2016.34     Document Type: Article

References (46)

1. Abul-Husn NS, Owusu Obeng A, Sanderson SC, Gottesman O, Scott SA. Implementation and utilization of genetic testing in personalized medicine. Pharmacogenomics Pers Med 2014; 7: 227-240.
2. Bank PC, Swen JJ, Guchelaar HJ. Pharmacogenetic biomarkers for predicting drug response. Expert Rev Mol Diagn 2014; 14: 723-735.
3. Swen JJ, Nijenhuis M, de Boer A, Grandia L, Maitland-van der Zee AH, Mulder H et al. Pharmacogenetics: from bench to byte-an update of guidelines. Clin Pharmacol Ther 2011; 89: 662-673.
4. Gharani N, Keller MA, Stack CB, Hodges LM, Schmidlen TJ, Lynch DE et al. The Coriell personalized medicine collaborative pharmacogenomics appraisal, evidence scoring and interpretation system. Genome Med 2013; 5: 93.
5. Khoury MJ. Genetics and genomics in practice: the continuum from genetic disease to genetic information in health and disease. Genet Med 2003; 5: 261-268.
6. Ramsey LB, Johnson SG, Caudle KE, Haidar CE, Voora D, Wilke RA et al. The clinical pharmacogenetics implementation consortium guideline for SLCO1B1 and simvastatin-induced myopathy: 2014 update. Clin Pharmacol Ther 2014; 96: 423-428.
7. Wilke RA, Ramsey LB, Johnson SG, Maxwell WD, McLeod HL, Voora D et al. The clinical pharmacogenomics implementation consortium: CPIC guideline for SLCO1B1 and simvastatin-induced myopathy. Clin Pharmacol Ther 2012; 92: 112-117.
8. Clinical Pharmacogenetics Implementation Consortium guidelines. http://www. pharmgkb.org (last accessed on 1 December 2015).
9. Mallal S, Phillips E, Carosi G, Molina JM, Workman C, Tomazic J et al. HLA-B5701 screening for hypersensitivity to abacavir. N Engl J Med 2008; 358: 568-579.
10. Link E, Parish S, Armitage J, Bowman L, Heath S, Matsuda F et al. SLCO1B1 variants and statin-induced myopathy-a genomewide study. N Engl J Med 2008; 359: 789-799.
11. Voora D, Shah SH, Spasojevic I, Ali S, Reed CR, Salisbury BA et al. The SLCO1B15 genetic variant is associated with statin-induced side effects. J Am Coll Cardiol 2009; 54: 1609-1616.
12. Janssens AC, Aulchenko YS, Elefante S, Borsboom GJ, Steyerberg EW, van Duijn CM. Predictive testing for complex diseases using multiple genes: fact or fiction? Genet Med 2006; 8: 395-400.
13. Kalf RR, Bakker R, Janssens AC. Predictive ability of direct-to-consumer pharmacogenetic testing: when is lack of evidence really lack of evidence? Pharmacogenomics 2013; 14: 341-344.
14. Brunham LR, Lansberg PJ, Zhang L, Miao F, Carter C, Hovingh GK et al. Differential effect of the rs4149056 variant in SLCO1B1 on myopathy associated with simvastatin and atorvastatin. Pharmacogenomics J 2012; 12: 233-237.
15. Carr DF, O'Meara H, Jorgensen AL, Campbell J, Hobbs M, McCann G et al. SLCO1B1 genetic variant associated with statin-induced myopathy: a proof-of-concept study using the clinical practice research datalink. Clin Pharmacol Ther 2013; 94: 695-701.
16. Gurwitz D, Pirmohamed M. Pharmacogenomics: the importance of accurate phenotypes. Pharmacogenomics 2010; 11: 469-470.
17. Finegold JA, Manisty CH, Goldacre B, Barron AJ, Francis DP. What proportion of symptomatic side effects in patients taking statins are genuinely caused by the drug? Systematic review of randomized placebo-controlled trials to aid individual patient choice. Eur J Prev Cardiol 2014; 21: 464-474.
18. DeJesus E, Herrera G, Teofilo E, Gerstoft J, Buendia CB, Brand JD et al. Abacavir versus zidovudine combined with lamivudine and efavirenz, for the treatment of antiretroviral-naive HIV-infected adults. Clin Infect Dis 2004; 39: 1038-1046.
19. Gulick RM, Ribaudo HJ, Shikuma CM, Lalama C, Schackman BR, Meyer WA III et al. Three-vs four-drug antiretroviral regimens for the initial treatment of HIV-1 infection: a randomized controlled trial. JAMA 2006; 296: 769-781.
20. Staszewski S, Keiser P, Montaner J, Raffi F, Gathe J, Brotas V et al. Abacavirlamivudine-zidovudine vs indinavir-lamivudine-zidovudine in antiretroviral-naive HIV-infected adults: a randomized equivalence trial. JAMA 2001; 285: 1155-1163.
21. Glas AS, Lijmer JG, Prins MH, Bonsel GJ, Bossuyt PM. The diagnostic odds ratio: a single indicator of test performance. J Clin Epidemiol 2003; 56: 1129-1135.
22. Baldessarini RJ, Finklestein S, Arana GW. The predictive power of diagnostic tests and the effect of prevalence of illness. Arch Gen Psychiatry 1983; 40: 569-573.
23. Khoury MJ, Newill CA, Chase GA. Epidemiologic evaluation of screening for risk factors: application to genetic screening. Am J Public Health 1985; 75: 1204-1208.
24. Mihaescu R, Moonesinghe R, Khoury MJ, Janssens AC. Predictive genetic testing for the identification of high-risk groups: a simulation study on the impact of predictive ability. Genome Med 2011; 3: 51.
25. Ma JD, Lee KC, Kuo GM. HLA-B5701 testing to predict abacavir hypersensitivity. PLoS Curr 2010; 2: RRN1203.
26. Schackman BR, Scott CA, Walensky RP, Losina E, Freedberg KA, Sax PE. The costeffectiveness of HLA-B5701 genetic screening to guide initial antiretroviral therapy for HIV. Aids 2008; 22: 2025-2033.
27. Stewart A. SLCO1B1 polymorphisms and statin-induced myopathy. PLoS Curr 2013; 4: 5.
28. Alfirevic A, Neely D, Armitage J, Chinoy H, Cooper RG, Laaksonen R et al. Phenotype standardization for statin-induced myotoxicity. Clin Pharmacol Ther 2014; 96: 470-476.
29. Yip VL, Marson AG, Jorgensen AL, Pirmohamed M, Alfirevic A. HLA genotype and carbamazepine-induced cutaneous adverse drug reactions: a systematic review. Clin Pharmacol Ther 2012; 92: 757-765.
30. Leckband SG, Kelsoe JR, Dunnenberger HM, George AL Jr, Tran E, Berger R et al. Clinical Pharmacogenetics Implementation Consortium guidelines for HLA-B genotype and carbamazepine dosing. Clin Pharmacol Ther 2013; 94: 324-328.
31. Caudle KE, Thorn CF, Klein TE, Swen JJ, McLeod HL, Diasio RB et al. Clinical Pharmacogenetics Implementation Consortium guidelines for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing. Clin Pharmacol Ther 2013; 94: 640-645.
32. Morel A, Boisdron-Celle M, Fey L, Soulie P, Craipeau MC, Traore S et al. Clinical relevance of different dihydropyrimidine dehydrogenase gene single nucleotide polymorphisms on 5-fluorouracil tolerance. Mol Cancer Ther 2006; 5: 2895-2904.
33. Caudle KE, Klein TE, Hoffman JM, Muller DJ, Whirl-Carrillo M, Gong L et al. Incorporation of pharmacogenomics into routine clinical practice: the Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline development process. Curr Drug Metab 2014; 15: 209-217.
34. Dunnenberger HM, Crews KR, Hoffman JM, Caudle KE, Broeckel U, Howard SC et al. Preemptive clinical pharmacogenetics implementation: current programs in five US medical centers. Annu Rev Pharmacol Toxicol 2015; 55: 89-106.
35. Gillis NK, Innocenti F. Evidence required to demonstrate clinical utility of pharmacogenetic testing: the debate continues. Clin Pharmacol Ther 2014; 96: 655-657.
36. Janssens AC, Deverka PA. Useless until proven effective: the clinical utility of preemptive pharmacogenetic testing. Clin Pharmacol Ther 2014; 96: 652-654.
37. Ratain MJ, Johnson JA. Meaningful use of pharmacogenetics. Clin Pharmacol Ther 2014; 96: 650-652.
38. Annemans L, Redekop K, Payne K. Current methodological issues in the economic assessment of personalized medicine. Value Health 2013; 16 (Suppl): S20-S26.
39. Deverka PA, Vernon J, McLeod HL. Economic opportunities and challenges for pharmacogenomics. Annu Rev Pharmacol Toxicol 2010; 50: 423-437.
40. Haga SB, LaPointe NM. The potential impact of pharmacogenetic testing on medication adherence. Pharmacogenomics J 2013; 13: 481-483.
41. Nicholson WT, Formea CM. Clinical Perspective on the Clinical Pharmacogenetics Implementation Consortium Updated 2014 Guidelines for CYP2D6 and Codeine. Clin Chem 2015; 61: 319-321.
42. Deeks JJ, Higgins J. Statistical Algorithms in Review Manager 5, 2010. http://ims. cochrane.org/revman/documentation/Statistical-methods-in-RevMan-5.pdf (last accessed on 1 December 2015).
43. Pagano M, Gauvreau K. Principles of Biostatistics. 2nd edn Brooks/Cole: Belmont, CA, 2000.
44. Hetherington S, Hughes AR, Mosteller M, Shortino D, Baker KL, Spreen W et al. Genetic variations in HLA-B region and hypersensitivity reactions to abacavir. Lancet 2002; 359: 1121-1122.
45. Mallal S, Nolan D, Witt C, Masel G, Martin AM, Moore C et al. Association between presence of HLA-B5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. Lancet 2002; 359: 727-732.
46. Martin AM, Nolan D, Gaudieri S, Almeida CA, Nolan R, James I et al. Predisposition to abacavir hypersensitivity conferred by HLA-B5701 and a haplotypic Hsp70-Hom variant. Proc Natl Acad Sci USA 2004; 101: 4180-4185.